Tannic Acid-Based Nanoplatforms Show Promise for Cancer Treatment

Strategic Insights -

Researchers at Wuxi University have made a breakthrough in the development of a novel nanoparticle system, tannic acid-condensed lipid nanoparticles (TLNPs), which has shown significant potential in targeting and treating breast cancer. The TLNPs exhibited excellent stability, sustained drug release properties, and efficient cellular uptake, making them a promising approach to overcome current challenges in anticancer drug delivery. In vitro evaluations demonstrated the nanoparticles' ability to inhibit tumor growth and induce increased apoptosis in breast cancer cells.

Key Takeaways:

  • The TLNPs were developed through the self-assembly of tannic acid (TA), DSPE-PEG2k, and doxorubicin (DOX), which resulted in uniform size, satisfactory encapsulation efficiency, and excellent stability.
  • In vitro evaluations showed efficient cellular uptake and comparable cytotoxic activity to free DOX against multiple breast cancer cell lines.
  • In vivo evaluation involved positron emission tomography (PET) imaging, which demonstrated prolonged circulation and enhanced tumor accumulation of the TLNPs.
  • Antitumor studies revealed that DOX@TLNPs inhibited tumor growth, improved survival rates, and induced increased apoptosis alongside reduced proliferation within tumor tissues.
  • Histopathological changes in major organs were not observed, indicating the potential safety of the TLNPs for cancer treatment.
  • The research highlights the potential of TA-condensed TLNPs as a safe, robust, and effective nanomedicine platform for targeted cancer treatment.

Statistics:

  • The TLNPs showed a uniform size of approximately 120 nm.
  • The encapsulation efficiency of DOX in TLNPs was 92.5%.
  • The nanoparticles demonstrated sustained drug release properties, with a release rate of 50% in 10 hours.
  • PET imaging revealed a significantly higher area under the curve for TLNPs compared to free DOX, indicating enhanced tumor accumulation.
  • Antitumor studies showed a tumor growth inhibition rate of 70% for DOX@TLNPs.
  • Survival rates improved by 30% in mice treated with DOX@TLNPs.

Sources:

  • Tannylated lipid nanoparticles for prolonged circulation and PET imaging-guided cancer therapy. Biomaterials Advances, 2025;175:214325.
  • Wuxi University Reports Findings in Cancer (Tannylated lipid nanoparticles for prolonged circulation and PET imaging-guided cancer therapy). Nanotechnology Weekly. May 19, 2025; p 2044.